• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Leadership Update

    2/5/25 4:04:50 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    natr-20250130
    0000275053false00002750532025-01-302025-01-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): January 30, 2025

     NS-logo-darkgreen.jpg
    NATURE’S SUNSHINE PRODUCTS, INC.
    (Exact name of registrant specified in its charter)
     
    Utah 001-34483 87-0327982
    (State or other jurisdiction of
    incorporation)
     (Commission File Number) (I.R.S. Employer Identification No.)
     2901 West Bluegrass Blvd., Suite 100
    Lehi, Utah 84043
    (Address of principal executive offices and zip code)

    Registrant’s telephone, including area code:  (801) 341-7900

    N/A
    (Former name and former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Title of each ClassTrading SymbolName of each exchange on which registered
    Common Stock, no par valueNATRNasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐



    Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On January 30, 2025, the Company’s Board of Directors appointed Ms. Katie A. May to its Board of Directors. Ms. May has been appointed to serve as a director until the next shareholders’ meeting at which directors are elected. Ms. May will serve on the Compensation and Governance Committees of the Board.

    Ms. May, 58, was previously the founder and Chief Executive Officer of Kidspot, an Australia based online publisher, eventually selling to News Corp in 2011. Katie became Chief Executive Officer at ShippingEasy, a Sydney based start-up in 2012, moved it to Austin, Texas, and built this ecommerce software solution to a leading player in the space, exiting to Stamps.com in mid-2016, joining their board in 2019. Following Stamps.com's acquisition of ShippingEasy, Katie also assumed leadership of St. Louis-based Shipworks, overseeing both companies until her retirement in 2020. Ms. May serves on the boards of directors of Vivi International Pty Ltd.,
    Australian education technology company, since February 2020, ROKT Pte Ltd., a global leader in ecommerce marketing technology, since July 2020, and Onramp Funds, Inc., a financing technology platform, since March 2021. Ms. May previously served on the board of directors of Stamps.com, Inc. (formerly NASDAQ: STMP), a leading provider of mailing and shipping services, Thinkific Labs, Inc. (TSX: THNC), a cloud-based software company for creators, and Pitney Bowes Inc. (NYSE:PBI), a global shipping and mailing company. Ms. May received an M.B.A. from The University of Texas at Austin and B.B.A. in Accounting from The University of Texas at Austin.
    The Board of Directors determined that Ms. May is an independent director under the current standards for independence established by NASDAQ.


    On February 4, 2025, Mr. Richard D. Moss notified the board of his decision to not stand for re-election at the company's upcoming 2025 annual shareholder meeting. His decision was not the result of a disagreement with the company.




    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
     NATURE’S SUNSHINE PRODUCTS, INC.
       
    Dated: February 5, 2025By:/s/ Nathan G. Brower
      Nathan G. Brower, Executive Vice President, General Counsel and Corporate Secretary

    Get the next $NATR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Wins Two Stevie® Awards in the 2025 American Business Awards®

      LEHI, Utah, April 24, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced it has been recognized with two prestigious Stevie® Awards in the 23rd Annual American Business Awards®. Nature's Sunshine received a Gold Stevie® Award for its 2023 Impact Report, which detailed the Company's achievements and progress in responsible business practices and sustainability. Additionally, the Company earned a Silver Stevie® Award for Achievement in Product Innovation for its new Chlorophyll Detoxifying Stick Packs. "We are deeply honored to be recognized by the American Business Awards," sai

      4/24/25 1:52:06 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DA Davidson resumed coverage on Nature's Sunshine with a new price target

      DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

      5/7/25 8:37:48 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

      Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

      9/13/24 7:38:59 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

      DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

      3/9/22 9:23:08 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fasching Steven J. was granted 8,000 shares, increasing direct ownership by 279% to 10,869 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/7/25 1:25:23 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Straus Robert D was granted 8,000 shares, increasing direct ownership by 18% to 52,014 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/6/25 3:42:40 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roering Tess was granted 8,000 shares, increasing direct ownership by 36% to 29,927 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/6/25 3:42:30 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nature's Sunshine Products Inc.

      10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      5/6/25 5:10:24 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      5/6/25 4:38:55 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nature's Sunshine Products Inc.

      DEF 14A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      3/20/25 10:09:21 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/12/24 10:37:49 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      1/31/24 11:56:05 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/13/23 2:42:04 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Financials

    Live finance-specific insights

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Sets First Quarter 2025 Conference Call for Tuesday, May 6, 2025, at 5:00 p.m. ET

      LEHI, Utah, April 22, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, May 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, May 6, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-free di

      4/22/25 4:04:59 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Reports Fourth Quarter and Full Year 2024 Financial Results

      LEHI, Utah, March 11, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were up 8.5% to $118.2 million compared to $108.9 million (up 10.0% in constant currency).GAAP net loss attributable to common shareholders of $0.3 million, or $(0.02) per diluted share, compared to net income of $9.0 million, or $0.46 per diluted share.Adjusted EBITDA up 6% to $10.3 million com

      3/11/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Katie A. May to Board of Directors

      LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine serving as independent directors. "Katie brings significant experience scaling and leading high-growth B2C, ecommerce and logistics companies," said Richard D. Moss, Chairman of the Board of Nature's Sunshine. "Her deep understanding of the full ecommerce lifecycle will strengthen and enhance our digital capabilities and drive s

      2/5/25 4:05:00 PM ET
      $NATR
      $PBI
      $STMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Office Equipment/Supplies/Services
      Miscellaneous
    • Nature's Sunshine Appoints Steven Fasching to Board of Directors

      LEHI, Utah, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Mr. Steven Fasching to its board of directors, effective November 6, 2024. Nature's Sunshine's board will now consist of nine directors with eight serving as independent directors. "We are delighted to welcome Steve to our expanded board of directors," said Richard D. Moss, Chairman of the Board for Nature's Sunshine. "He brings significant financial acumen and public company experience from well-known consumer brands and will be a valuable addition to our board. Ste

      11/11/24 4:05:00 PM ET
      $DECK
      $NATR
      Shoe Manufacturing
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care